← Research ProtocolsIpamorelin
STUDIED EXPOSURE MAP / 1999
Ipamorelin
tested in research.
The actual doses, concentrations or exposure levels reported by the source — kept attached to route, population, timeframe and evidence type.
HUMAN / DOSE ESCALATION PK + PDPHARMACEUTICAL RESEARCHSTUDIED EXPOSURE ≠ RECOMMENDED DOSE
STUDIED EXPOSURE / SOURCE DATANumbers below describe this research source only.
4.21 nmol/kg
IV over 15 min
14.02 nmol/kg
IV over 15 min
42.13 nmol/kg
IV over 15 min
84.27 nmol/kg
IV over 15 min
140.45 nmol/kg
IV over 15 min
Context: The published human study used intravenous infusion. It should not be converted into a subcutaneous consumer protocol.
NOT A DOSING GUIDEENHANCED is reporting what researchers administered or tested. It does not convert these numbers into a personal dose, reconstitution plan, cycle, titration schedule or recommendation.
SOURCE / PHARMACEUTICAL RESEARCH
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers
Study design and tested exposure are separated from recommendation. Route and population stay visible so the numbers cannot be read without context.
1999
01 / DESIGNDose-escalation pharmacokinetic/pharmacodynamic study
02 / POPULATION / MODELHealthy male volunteers · eight subjects per exposure level
03 / ROUTEIntravenous infusion over 15 minutes
04 / TIMEFRAMEAcute PK/PD study
05 / PRIMARY QUESTIONIpamorelin concentrations and GH response
It supports a factual statement about the exposure tested in this research source. It does not establish that the same exposure is appropriate, effective or safe outside that source.
Growth-hormone secretagogue research
Study exposure ≠ personal protocol. Animal doses are never converted to human-equivalent amounts here. IV, topical, oral, intranasal and subcutaneous exposures are not treated as interchangeable.